Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

Paladin Labs Inc (PLB.TO)

PAST TOP PICK
(Top Pick Aug 6/10, Up 49.39%) There is a big earnings revision coming. A superb company. It is under rated in Canada.
TOP PICK
Superb management team. Management team has to grow company at 15% per year to make their bonus. Pharma. The story is not anywhere close to being over.
PAST TOP PICK
(A Top Pick June 29/10. Up 83.23%.) Pharmaceuticals. Have been trading at a very low multiple. Good management. Generates a phenomenal amount of excess cash flow. Still a Buy.
PAST TOP PICK
(Top Pick Mar 23/10, Up 72.00%) His second largest position. This company has so much on the go. Even if you are pessimistic on the economy, it will grow 20% next year
TOP PICK
Good opportunity, sales and marketing of drugs in Canada and other countries. They buy or license rights from others. 9% 4-quarter trailing cash flow yield. Cash is more than 25% of their market cap.
TOP PICK
Earnings grow is forecasted at 24% form $1.02 to $1.27 to 2011 and a further 40% growth to 2012. About $110 million cash on hand, which may be used for accretive acquisitions.
BUY
Fantastic company and is moving onto emerging markets.
TOP PICK
Pipeline for small drug companies. Just had a fantastic quarter. Great risk/reward stock. Over $100 million cash and no debt.
TOP PICK
Single digit cash/earnings ratio. Extremely profitable. They are highly incentivised to grow the company by at least 15% a year. Balance sheet is oozing with cash. Minimizes risk. Could grow at 20% per year for the next 5 years. Low Risk Pharmaceuticals.
TOP PICK
A great company for years but now moving into emerging markets. Loved it before and even more after the acquisition.
WAIT
Good earnings and growth. May pause for a while.
Showing 16 to 26 of 26 entries